Gla domains as targeting agents

Patent metadata

Field	Value
Publication number	US-9694048-B2
Application number	US-201414773068-A
Country	US
Kind code	B2
Filing date	Mar 13, 2014
Priority date	Mar 15, 2013
Publication date	Jul 4, 2017
Grant date	Jul 4, 2017

Abstract

The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.

First claim

The invention claimed is:

1. A method of targeting cell membrane phosphatidylserine comprising:
(a) providing an isolated polypeptide of from 4.5 to 30 kD in size comprising a gamma-carboxyglutamic-acid (Gla) domain with 5-15 Gla residues, a protein S EGF domain and lacking a protease or hormone-binding domain; and
(b) contacting said peptide with a cell surface in vitro or ex vivo,

wherein said polypeptide binds to phosphatidylserine on said cell membrane.

2. The method of claim 1 , wherein said cell membrane is a cardiac cell membrane, a neuronal cell membrane, an endothelial cell membrane, a virus-infected cell membrane, an apoptotic cell membrane, a platelet membrane or a cancer cell membrane.

3. The method of claim 1 , wherein said polypeptide further comprises a detectable label, wherein said detectable label comprises a fluorescent label, a chemiluminescent label, a radio label, an enzyme, a dye, or a ligand.

4. The method of claim 1 , wherein said polypeptide comprises 300 residues or less.

5. The method of claim 1 , wherein said polypeptide comprises from 1-5 disulfide bonds.

6. The method of claim 1 , wherein said polypeptide further comprises an antibody Fc region.

Assignees

• Bayer Healthcare Llc
• Bayer Healthcare Llc

Inventors

• Bauzon Maxine
• Hermiston Terry

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P5/38

  of the suprarenal hormones · CPC title